New eye drops aim to soothe red eyes fast
NCT ID NCT07531043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests an investigational eye drop (FID123472) containing apraclonidine to reduce redness in adults with minor eye irritation. About 230 participants will receive either the active drop or a placebo (vehicle). The main goals are to see if redness improves within 15 minutes and lasts up to 14 hours.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Apraclonidine ophthalmic solution (0.125%)
- What this could lead to
- If successful, this could provide a new prescription option for quickly and safely reducing eye redness from minor irritations.
- What could go wrong
- This is a Phase 3 trial, but it's testing a known drug in a new formulation. The effect may be modest or short-lived, and side effects like eye irritation or allergic reactions are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OCULAR HYPEREMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Contact Alcon Call Center for Trial Locations
Fort Worth, Texas, 76134, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.